Metabolic Interactions in the Tumor Microenvironment

Trends in Cell Biology

Volumn 27, Issue 11, 2017, Pages 863-875

  Lyssiotis, Costas A ^a   Kimmelman, Alec C ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer associated fibroblasts; crosstalk; hypoxia; immune; stroma

Indexed keywords

AMINO ACID; FATTY ACID; GLUCOSE; LACTIC ACID;

AMINO ACID METABOLISM; CANCER CELL; CELL INTERACTION; CELL ORGANELLE; FATTY ACID METABOLISM; GLYCOLYSIS; HUMAN; IMMUNOCOMPETENT CELL; MACROMOLECULE; METABOLISM; METABOLITE; NONHUMAN; NUTRIENT; PARENCHYMA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYMBIOSIS; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; CANCER ASSOCIATED FIBROBLAST; CELL COMMUNICATION; ENERGY METABOLISM; MACROPHAGE; NEOPLASM; PATHOLOGY;

AMINO ACIDS; CANCER-ASSOCIATED FIBROBLASTS; CELL COMMUNICATION; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HUMANS; MACROPHAGES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85024500637     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2017.06.003     Document Type: Review

References (118)

1. Egeblad, M., et al. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18 (2010), 884–901.
2. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
3. Makohon-Moore, A., Iacobuzio-Donahue, C.A., Pancreatic cancer biology and genetics from an evolutionary perspective. Nat. Rev. Cancer 16 (2016), 553–565.
4. Davidson, S.M., et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23 (2016), 517–528.
5. Mayers, J.R., et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353 (2016), 1161–1165.
6. Yuneva, M.O., et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15 (2012), 157–170.
7. Carmona-Fontaine, C., et al. Metabolic origins of spatial organization in the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 2934–2939.
8. Christen, S., et al. Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep. 17 (2016), 837–848.
9. Hensley, C.T., et al. Metabolic heterogeneity in human lung tumors. Cell 164 (2016), 681–694.
10. Sellers, K., et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Invest. 125 (2015), 687–698.
11. Moscat, J., et al. p62 in cancer: signaling adaptor beyond autophagy. Cell 167 (2016), 606–609.
12. Valencia, T., et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26 (2014), 121–135.
13. Kalluri, R., The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16 (2016), 582–598.
14. DuFort, C.C., et al. Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophys. J. 110 (2016), 2106–2119.
15. Jain, R.K., et al. The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 16 (2014), 321–346.
16. DuFort, C.C., et al. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology 150 (2016), 1545–1557.e2.
17. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
18. Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
19. Choi, S.Y., et al. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?. J. Pathol. 230 (2013), 350–355.
20. Brand, A., et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24 (2016), 657–671.
21. Colegio, O.R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
22. Gajewski, T.F., et al. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
23. Vonderheide, R.H., Bayne, L.J., Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol. 25 (2013), 200–205.
24. Gabrilovich, D.I., et al. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
25. Johnson, M.O., et al. Nutrients and the microenvironment to feed a T cell army. Semin. Immunol. 28 (2016), 505–513.
26. Langston, P.K., et al. Metabolism supports macrophage activation. Front. Immunol., 8, 2017, 61.
27. Geeraerts, X., et al. Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. Front. Immunol., 8, 2017, 289.
28. Allaman, I., et al. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 34 (2011), 76–87.
29. Yamanishi, S., et al. Extracellular lactate as a dynamic vasoactive signal in the rat retinal microvasculature. Am. J. Physiol. Heart. Circ. Physiol. 290 (2006), H925–H934.
30. Schwarcz, R., et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13 (2012), 465–477.
31. Felig, P., The glucose-alanine cycle. Metabolism. 22 (1973), 179–207.
32. Anastasiou, D., Tumour microenvironment factors shaping the cancer metabolism landscape. Br. J. Cancer 116 (2017), 277–286.
33. Murray, P.J., Amino acid auxotrophy as a system of immunological control nodes. Nat. Immunol. 17 (2016), 132–139.
34. Birsoy, K., et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508 (2014), 108–112.
35. LeBleu, V.S., et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16 (2014), 992–1003 1–15.
36. Sancho, P., et al. MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 22 (2015), 590–605.
37. Viale, A., et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514 (2014), 628–632.
38. Boudreau, A., et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat. Chem. Biol. 12 (2016), 779–786.
39. Kennedy, K.M., et al. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PLoS One, 8, 2013, e75154.
40. Sotgia, F., et al. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu. Rev. Pathol. 7 (2012), 423–467.
41. Draoui, N., Feron, O., Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis. Model. Mech. 4 (2011), 727–732.
42. Doherty, J.R., Cleveland, J.L., Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123 (2013), 3685–3692.
43. Sonveaux, P., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118 (2008), 3930–3942.
44. Guillaumond, F., et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3919–3924.
45. Allen, E., et al. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 15 (2016), 1144–1160.
46. Pisarsky, L., et al. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep. 15 (2016), 1161–1174.
47. Dienel, G.A., Brain lactate metabolism: the discoveries and the controversies. J. Cereb. Blood Flow Metab. 32 (2012), 1107–1138.
48. Kasparov, S., Are astrocytes the pressure-reservoirs of lactate in the brain?. Cell Metab. 23 (2016), 1–2.
49. De Saedeleer, C.J., et al. Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS One, 7, 2012, e46571.
50. Lee, D.C., et al. A lactate-induced response to hypoxia. Cell 161 (2015), 595–609.
51. Ruan, G.X., Kazlauskas, A., Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J. Biol. Chem. 288 (2013), 21161–21172.
52. Vegran, F., et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 71 (2011), 2550–2560.
53. Fiaschi, T., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 72 (2012), 5130–5140.
54. Zhang, D., et al. Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation. Cell Rep. 10 (2015), 1335–1348.
55. Pavlides, S., et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. ABBV Cell Cycle 8 (2009), 3984–4001.
56. Rattigan, Y.I., et al. Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp. Cell Res. 318 (2012), 326–335.
57. Koukourakis, M.I., et al. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 66 (2006), 632–637.
58. Sousa, C.M., et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536 (2016), 479–483.
59. Yang, L., et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 24 (2016), 685–700.
60. Chang, C.H., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
61. Ho, P.C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228.
62. Kamphorst, J.J., et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75 (2015), 544–553.
63. Salimian Rizi, B., et al. Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells. Cancer Res. 75 (2015), 456–471.
64. Grippo, P.J., et al. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut 61 (2012), 1454–1464.
65. Zyromski, N.J., et al. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 146 (2009), 258–263.
66. Rebours, V., et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin. Cancer Res. 21 (2015), 3522–3528.
67. Lyssiotis, C.A., et al. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle 12 (2013), 1987–1988.
68. Son, J., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496 (2013), 101–105.
69. Meyer, K.A., et al. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Biochem. Biophys. Rep. 7 (2016), 144–149.
70. Incio, J., et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov. 6 (2016), 852–869.
71. Philip, B., et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 145 (2013), 1449–1458.
72. Tajan, M., Vousden, K.H., The quid pro quo of the tumor/stromal interaction. Cell Metab. 24 (2016), 645–646.
73. Tardito, S., et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17 (2015), 1556–1568.
74. Sullivan, L.B., Chandel, N.S., Mitochondrial reactive oxygen species and cancer. Cancer Metab., 2, 2014, 17.
75. Zhang, W., et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol. 14 (2012), 276–286.
76. Wang, W., et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165 (2016), 1092–1105.
77. Mellor, A.L., Munn, D.H., Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8 (2008), 74–80.
78. Munn, D.H., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998), 1191–1193.
79. Munn, D.H., et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999), 1363–1372.
80. Munn, D.H., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22 (2005), 633–642.
81. Opitz, C.A., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 (2011), 197–203.
82. Mezrich, J.D., et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185 (2010), 3190–3198.
83. Nguyen, N.T., et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 19961–19966.
84. Platten, M., et al. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72 (2012), 5435–5440.
85. Fletcher, M., et al. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 75 (2015), 275–283.
86. Rodriguez, P.C., et al. L-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109 (2007), 1568–1573.
87. Rodriguez, P.C., et al. L-Arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171 (2003), 1232–1239.
88. Geiger, R., et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167 (2016), 829–842.e13.
89. Bowles, T.L., et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int. J. Cancer 123 (2008), 1950–1955.
90. Kim, R.H., et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 69 (2009), 700–708.
91. Nieman, K.M., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17 (2011), 1498–1503.
92. Balaban, S., et al. Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab., 5, 2017, 1.
93. Chaudhri, V.K., et al. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol. Cancer Res. 11 (2013), 579–592.
94. Zhao, H., et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife, 5, 2016, e10250.
95. Achreja, A., et al. Exo-MFA – A 13C metabolic flux analysis to dissect tumor microenvironment-secreted exosome contributions towards cancer cell metabolism. Metab. Eng., 2017, 10.1016/j.ymben.2017.01.001 Published online January 11, 2017.
96. Rogers, R.S., Bhattacharya, J., When cells become organelle donors. Physiology (Bethesda) 28 (2013), 414–422.
97. Spees, J.L., et al. Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 1283–1288.
98. Tan, A.S., et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 21 (2015), 81–94.
99. Moschoi, R., et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood 128 (2016), 253–264.
100. Lorendeau, D., et al. Metabolic control of signalling pathways and metabolic auto-regulation. Biol. Cell 107 (2015), 251–272.
101. Husain, Z., et al. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191 (2013), 1486–1495.
102. Calcinotto, A., et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 72 (2012), 2746–2756.
103. Hutcheson, J., et al. Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease. Clin. Cancer Res. 22 (2016), 3606–3617.
104. Chen, P., et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 580–585.
105. Antonioli, L., et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13 (2013), 842–857.
106. Idzko, M., et al. Nucleotide signalling during inflammation. Nature 509 (2014), 310–317.
107. Burnstock, G., Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev. 58 (2006), 58–86.
108. Di Virgilio, F., Adinolfi, E., Extracellular purines, purinergic receptors and tumor growth. Oncogene 36 (2017), 293–303.
109. Hasko, G., et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7 (2008), 759–770.
110. Ohta, A., Sitkovsky, M., Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 (2001), 916–920.
111. Deaglio, S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204 (2007), 1257–1265.
112. Blay, J., et al. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57 (1997), 2602–2605.
113. Pavlova, N.N., Thompson, C.B., The emerging hallmarks of cancer metabolism. Cell Metab. 23 (2016), 27–47.
114. Sherman, M.H., et al. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 1129–1134.
115. Ying, H., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 (2012), 656–670.
116. Guan, K.L., Xiong, Y., Regulation of intermediary metabolism by protein acetylation. Trends Biochem. Sci. 36 (2011), 108–116.
117. Halestrap, A.P., Monocarboxylic acid transport. Compr. Physiol. 3 (2013), 1611–1643.
118. Pellerin, L., Magistretti, P.J., Sweet sixteen for ANLS. J. Cereb. Blood Flow Metab. 32 (2012), 1152–1166.